143 results about "Gelatinase" patented technology

Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

The invention concerns a peptide extract of lupine (lupinus) characterised in that it has a metalloprotease inhibiting activity, in particular collagenase and gelatinase. The invention also concerns a pharmaceutical, cosmetic or nutritional composition comprising a peptide extract, optionally an inert carrier, in particular for treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease.

Disclosed is a neutrophil gelatinase-associated lipocalin (NGAL) protein level ELISA kit which is composed of a reagent I and a reagent II. The reagent I comprises a slow-release agent and a denaturant; the reagent II comprises latex particles coated with NGAL antibodies. Aggregated protein is denatured to some extent after being added with the denaturant, physical and (or) chemical binding site is exposed, chemical binding action of the chemical binding site is fractured through sulfydryl dissociation agent , while physical binding action of the physical binding site is dispersed by surface active agent, so that the aggregated protein is disaggregated. Therefore, it is quite important to choose the appropriate types and concentrations of denaturant, sulfydryl dissociation agent, and surface active agent; the aggregate is disaggregated without interference on following immunological detection. According to the method, the the appropriate types and concentrations of denaturant, sulfydryl dissociation agent and surface active agent are determined and chosen specifically, which solves the technical problem above.

The invention relates to a method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in a sample. The method comprises the following steps of: reacting an antibody of the NGAL with human NGAL of a specimen to be detected to form a compound which causes turbidity change; characterizing the change by using light projection intensity or light scattering intensity; and finding out the content of the human NGAL in the specimen to be detected from the concentration of the NGAL standard product and a standard curve of corresponding light scattering intensity or light transmission intensity. The method has the advantages of high sensitivity, high recovery rate and good repeatability, and a detection measure having the advantages of simplicity, convenience, good repeatability, strong adaptability and high speed is determined for measuring the NGAL in the samples of urine or blood plasma, and the like.

Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.

The invention relates to a kit for assaying NGAL in serum, and provides an NGAL assay kit suitable for a full-automatic biochemical analyzer and a special protein analyzer. The technical scheme includes that the NGAL assay kit comprises reagent R1, reagent R2 and a calibrator, wherein the reagent R1 is composed of a buffer solution, an accelerator, a surfactant and the balance purified water; the reagent R2 is composed of a buffer solution and latex microspheres combined with anti-human NGAL antibodies; and the calibrator is composed of a buffer solution, a stabilizer, a preservative, a certain amount of pure recombinant human NGAL required by concentration, and the balance purified water. The NGAL content in the serum can be quickly assayed through the reagent combination.

The invention relates to a method for diagnosing, evaluating or testing a cancer and foreseeing the severity of the cancer. The testing method comprises the following steps: an antibody of anti-human tropic neutrophil gelatinase-associated lipocalin (NGAL) is reacted with the human NGAL of a specimen to be tested to form a compound which causes turbidity change; light protection intensity or light scattering intensity is used for presenting the change; the human NGAL content of the specimen to be tested is tested through a standard curve of the concentration of human NGAL standard to relevant light protection intensity or light scattering intensity; and finally the cancer severity is measured based on the tested NGAL content. The method has the advantages of high flexibility, high recovery and good repetitiveness, determines a testing method with great convenience, good repetitiveness and strong suitability for the NGAL in urine or blood plasma of a cancer patient, and provides possibility for the clinical directive function of human NGAL and further research of the functions of the human NGAL.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The present invention is one kind of tubular ultrafiltering and clarification and reeling ultrafiltering and separation combined process for separating apple protein, apple polyphenol, apple starch and pigment from apple juice. The process can lower the color value of apple juice, raise the quality one apple juice and utilize apple juice comprehensively. The process includes the steps of material screening, washing, drying, crushing and squeezing to obtain apple juice and apple residue, pasteurizing, enzymolysis with pectase and gelatinase, tubular ultrafiltering and clarification to obtain clear juice, great molecular weight protein, cellulose, starch and pectin, reeling ultrafiltering and separation to obtain purified juice and concentrate with rich apple polyphenol, small molecular weight protein and pigment, treating clear apple juice to eliminate pesticide residue and heavy metal and concentration, and ultrahigh temperature short-time sterilization of apple juice.

The invention relates to an immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and a preparation method thereof; an application liquid bottle, an antibody suspending liquid bottle and a standard substance bottle are placed in a box body; application liquid is arranged in the application liquid bottle, and comprises the following components of: 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative, 1 percent to 20 percent of sodium chloride and 20mmol/l to 200mmol/l of buffer solution; the antibody suspending liquid bottle contains emulsion suspension which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, and the emulsion suspension has the following components of: 0.05 percent to 0.5 percent of emulsion which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative and 20mmol/l to 200mmol/l of buffer solution; and the standard substance bottle contains the standard substances of the lipid carrier protein related to the neutrophils gelatinase. According to the invention, the mass quantitative detection on a biochemical instrument is realized.

The invention relates to an oil-degradation oil-and-salt tolerance bacterial strain which is named as SY-1. The systematic name of the SY-1 is Escherichia coli, the file number is CGMCC (China General Microbiological Culture Collection Center No.7075, the file date is December 31, 2012, the file address is the Micro-organism Study of Chinese Academy of Sciences, No.3, No.1 Beichen west road, Chaoyang district, Beijing city, and the file unit is China General Microbiological Culture Collection Center. The oil-degradation oil-and-salt tolerance bacterial strain is good in oil and salt tolerance, is Gram-negative bacterium shaped in short rhabditiform and with flagellum and no spores and active, is in citrate and glucose ammonium salt positive property and can generate catalase without gelatinase. The bacterial strain is fast in growth, can grow in oil used as unique carbon source, and has the advantages of oil degradation.

The object of the present invention is to provide a method for screening a substance that affects gelatinase-mediated EphA4 processing. The present invention provides a method for screening a substance that affects gelatinase-mediated EphA4 processing, which comprises the steps of: (a) allowing a first biological composition containing gelatinase or a biologically active fragment thereof to be contacted with a second biological composition containing EphA4 in the presence and absence of a candidate substance; (b) measuring the presence or amount of the EphA4 ectodomain and/or endodomain fragment; and (c) selecting the candidate substance as a substance that affects gelatinase-mediated EphA4 processing if the results of the step (b) measured in the presence of the candidate substance are changed in comparison with the results of the step (b) measured in the absence of the candidate substance.

The invention discloses a hybridoma cell strain 3B1 and a hybridoma cell strain 4C2 and a mouse anti-human NGAL monoclonal antibody 3B1 and a mouse anti-human NGAL monoclonal antibody4C2 produced respectively. The two kinds of monoclonal antibodies belong to a same immunoglobulin G (IgG) 2a subclass, but identify various epitopes and can perform specific binding to NGAL recombinant protein with amino acid sequences represented by SEQ ID NO.1. The two monoclonal antibodies can be applied to detect the concentration of the NGAL in human body fluids and have significant application prospect.

The invention discloses a neutrophil gelatinase-associated lipocalin determination kit. The kit comprises a reagent R1 and a reagent R2 which are liquid components and are mutually independent, the reagent R1 comprises a buffer solution, inorganic salt ions, an accelerator, a chelating agent, a stabilizer, an antiseptic and an anti-humanr heumatoid factor antibody, and the reagent R2 comprises the buffer solution, the stabilizer, a suspending aid, a surfactant, the antiseptic and a latex coated anti-human neutrophil gelatinase-associated lipocalin. The preparation method comprises the following steps: preparing the reagents according to the component content; mixing a sample to be determined with the reagent R1 and the reagent R2 to fully react the sample to be determined with the reagent R1 and the reagent R2; determining the absorbance difference by using a fully-automatic biochemical analyzer after the reaction; and calculating the concentration of neutrophil gelatinase-associated lipocalin in the sample according to the absorbance change value. The kit has high accuracy.

The invention belongs to the medical field and particularly relates to an acute kidney injury diagnosis technology, a B cell epitope peptide of human NGAL (Neutrophil Gelatinase Associated Lipocalin) and a hybridoma cell prepared by same, and an application of the B cell epitope peptide and a specific antibody thereof and an immune complex of the specific antibody in preparing diagnostic reagent for acute kidney injury. The B cell epitope peptide prepared by the invention immunizes a monoclonal antibody prepared by adopting a rat and has the advantages of high purity (The SDS (Sodium Dodecyl Sulfate)-PAGE (PolyAcrylamide Gel Electrophoresi) detection purity is more than 96 percent), high valence (the ELISA (Enzyme-Linked Immuno Sorbent Assay) valence reaches 1:256000), good specificity, mass preparation and the like; and through the monoclonal antibody and a polyclonal antibody prepared by the B cell epitope peptide, the B cell epitope peptide can be used for detecting the content of the NGAL in the urine of a patient, for example, by adopting a double antibody sandwich ELISA reaction mode, a double antibody sandwich structure formed by an enzyme labeled human anti-NGAL monoclonal antibody, an enzyme labeled plate package anti-NGAL polyclonal antibody and a measured sample NGAL antigen is detected.

The invention discloses a polypeptide hydrogel. The polypeptide hydrogel is prepared by mixing a self-assembled peptide (SAP) aqueous solution with exosomes (Exos). The present invention also discloses a preparation method and application of the polypeptide hydrogel. The polypeptide hydrogel provided by the invention can effectively slow down the release of the Exos and prolong the half-life of the Exos; and the released Exos have the activity similar to that of newly-separated Exos, and can effectively reduce HK2 cell injury caused by hypoxia and promote the recovery of vascular endothelial damage. The polypeptide hydrogel disclosed by the invention is capable of effectively reducing acute kidney injury and slowing down renal fibrosis by reducing kidney cell apoptosis and inflammatory factors, the expression amount of kidney injury marker protein-neutrophil gelatinase-related apolipoprotein (NGAL), and the synthesis and secretion of renal extracellular matrix (ECM), and has a good clinical application prospect.

A transgenic mammal, including a transgenic mouse, whose genome comprises a transgene, said transgene comprises a neutrophil gelatinase-associated lipocalin (NGAL) promoter gene operably linked to at least one sequence encoding at least one of a fluorescent or bioluminescent protein, wherein the NGAL promoter gene expression in the mouse can be assayed by bioluminescence or fluorescence imaging.

The invention discloses recombinant neutrophil gelatinase associated lipocalin and a preparation method thereof. The preparation method of the recombinant neutrophil gelatinase associated lipocalin antibody belonging to the technical fields of biological science and transthyretin comprises the following steps: analyzing an NGAL (neutrophil gelatinase associated lipocalin) epitope; synthesizing the recombinant NGAL; separately purifying the recombinant NGAL; preparing an anti-rabbit recombinant NGAL antibody; collecting and separating to obtain an antiserum purified antibody containing the antibody, so as to obtain the anti-NGAL antibody. By adopting the preparation method, the problem of low yield in preparation of a multi-antibody by a natural full-length protein is solved; meanwhile, the antibody prepared by the preparation technology disclosed by the invention has good specificity; the problem that the traditional neutrophil gelatinase associated lipocalin antibody cannot completely meet a western blot immunohistochemical experiment and an enzyme-linked immunosorbent assay is also solved.

The invention discloses a hybridoma cell strain generating an anti-human NGAL specific monoclonal antibody and a monoclonal antibody generated by the same. The hybridoma cell strain is generated in a way that after an amino acid sequence shown by SEQIDNO:1 immunizes a Balb/c rat, a spleen B lymph cell and a myeloma cell of the rat are fused for further cultivation. The antibody can be used for the immunity detection of the NGAL. Based on the invention, an immunity detection reagent for the NGAL can be developed and used for diagnosing and detecting acute kidney injury and other diseases.